1887
Surveillance and outbreak report Open Access
Like 0

Abstract

The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season’s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0–61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6–64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6) against influenza B. In 2–17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6–94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.38.30348
2016-09-22
2017-11-18
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.38.30348
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/38/eurosurv-21-30348-4.html?itemId=/content/10.2807/1560-7917.ES.2016.21.38.30348&mimeType=html&fmt=ahah

References

  1. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14 – extension to children. London: Department of Health; 26 Jul 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013.pdf
  2. Public Health England (PHE). Flu plan. Winter 2015/16. London: PHE; May 2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526143/Flu_Plan_Winter_2015_to_2016superseded.pdf
  3. Centers for Disease Control and Prevention (CDC). ACIP votes down use of LAIV for 2016-2017 flu season. Media statement. Atlanta: CDC; 22 Jun 2016. Available from: http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html
  4. Public Health England (PHE). Surveillance of influenza and other respiratory viruses in the United Kingdom: Winter 2015 to 2016. London: PHE; 17 Mar 2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526405/Flu_Annual_Report_2015_2016.pdf
  5. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. Euro Surveill. 2016;21(13):30179.  https://doi.org/10.2807/1560-7917.ES.2016.21.13.30179  PMID: 27074651 
  6. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010;64(12):1062-7.  https://doi.org/10.1136/jech.2009.093450  PMID: 19910645 
  7. Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill. 2014;19(27):20851.  https://doi.org/10.2807/1560-7917.ES2014.19.27.20851  PMID: 25033051 
  8. Ellis J, Iturriza M, Allen R, Bermingham A, Brown K, Gray J, et al. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill. 2009;14(22):19230. PMID: 19497254 
  9. Gunson R, Maclean A, Davies E, Bennett S, Miller R, Carman WF. Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. J Virol Methods. 2010;163(2):258-61.  https://doi.org/10.1016/j.jviromet.2009.10.006  PMID: 19854220 
  10. Galiano M, Agapow P-M, Thompson C, Platt S, Underwood A, Ellis J, et al. Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One. 2011;6(8):e23779.  https://doi.org/10.1371/journal.pone.0023779  PMID: 21887318 
  11. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418-25.  https://doi.org/10.1128/JVI.77.15.8418-8425.2003  PMID: 12857911 
  12. Zambon M. Laboratory Diagnosis of Influenza. In: Nicholson K, Hay A, Webster RG, editors. Textbook of Influenza. Oxford: Blackwell Science; 1998. pp. 291-313].</edb>
  13. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725-9.  https://doi.org/10.1093/molbev/mst197  PMID: 24132122 
  14. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011;16(6):19791. PMID: 21329644 
  15. Kissling E, Valenciano M. Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study. Euro Surveill. 2016;21(6):30134.  https://doi.org/10.2807/1560-7917.ES.2016.21.6.30134  PMID: 26898240 
  16. Chambers C, Skowronski D, Sabaiduc S, Winter A, Dickinson J, De Serres G, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill. 2016;21(11):30168.
  17. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-17 northern hemisphere influenza season. Geneva: WHO; 25 February 2016. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en
  18. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40.  https://doi.org/10.1093/infdis/jiu647  PMID: 25406334 
  19. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):30139.  https://doi.org/10.2807/1560-7917.ES.2016.21.7.30139  PMID: 26924024 
  20. Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016;34(1):77-82.  https://doi.org/10.1016/j.vaccine.2015.11.010  PMID: 26589519 
  21. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds – a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016;21(38):30346.  https://doi.org/10.2807/1560-7917.ES.2016.21.38.30346 
  22. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines. 2011;10(8):1131-41.  https://doi.org/10.1586/erv.11.73  PMID: 21854309 
  23. Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill. 2015;20(39):30029.  https://doi.org/10.2807/1560-7917.ES.2015.20.39.30029  PMID: 26537222 
  24. Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014;19(22):20823.  https://doi.org/10.2807/1560-7917.ES2014.19.22.20823  PMID: 24925457 
  25. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16):30201.  https://doi.org/10.2807/1560-7917.ES.2016.21.16.30201  PMID: 27124420 
  26. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36(3):623-31.  https://doi.org/10.1093/ije/dym021  PMID: 17403908 
/content/10.2807/1560-7917.ES.2016.21.38.30348
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error